All In Biotech

Drug Trial Radar · NCT05085977

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Mar 10, 2022

Primary completion

Sep 3, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
Protara TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. Dosing will start in subjects with HGTa or CIS (including CIS with concomitant Ta), and all subjects will receive 6 weeks of treatment at a fixed volume with varying dose levels.

Conditions

  • Non-muscle Invasive Bladder Cancer

Interventions

  • TARA-002Biological

    Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a, Dose Escalation Phase: Incidence of DLT AEs in subjects with HGTa or CIS NMIBCTime frame: Day 1 to Day 43
  2. Phase 1a, Dose Escalation Phase: MTD and RP2D of TARA-002 in subjects with HGTa or CIS NMIBCTime frame: Day 1 to Day 43

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • USC Norris Cancer Center

    Los Angeles, California

  • Mayo Clinic

    Jacksonville, Florida

  • Tulane Medical Center

    New Orleans, Louisiana

  • Chesapeake Urology Research Associates

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • New Jersey Urology

    Mount Laurel, New Jersey

  • Premier Medical Group of the Hudson Valley

    Poughkeepsie, New York

  • University of Rochester, Department of Urology

    Rochester, New York

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology Associates PC

    Nashville, Tennessee

  • UT Health San Antonio

    San Antonio, Texas

  • PMSI Republican Clinical Hospital "T. Mosneaga," ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, Moldova

  • Spitalul Clinic de Nefrologie Carol Davila

    Bucharest, Romania

  • Arensia Kapitanivka

    Kapitanivka, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.